Name: BIM-IOL System in Open-angle glaucoma or ocular hypertension: Dosage
Published: 2026-09-17T18:17:42-04:00

Product information and disease description Product description Product information Dosing and administration

Dosage

4 evidence topics · 2 sources

Intended commercial dose and duration

“For SpyGlass Pharma’s intended commercial dose of 78-mcg, patients receiving the BIM-IOL System achieved robust clinical improvement:” (opens the source at this quote in a new tab)

“In July 2025, we initiated two identical, registrational, Phase 3 clinical trials to evaluate the BIM-IOL System with 78 mcg of bimatoprost, which is designed to consistently deliver three years of bimatoprost.” (opens the source at this quote in a new tab)

Single eye treated per participant in clinical trials

“Enrolled patients who meet the surgical eligibility criteria will receive cataract surgery in one eye (the study eye) after receiving a baseline washout of all IOP-lowering medications.” (opens the source at this quote in a new tab)

Dose levels studied: first-in-human study

“Enrolled patients were sequentially assigned 1:1:1 into three groups, where patients received a BIM-IOL System containing 75, 150 or 300 mcg of bimatoprost that continuously released a low (1x), mid (2x) or high (4x) dose of bimatoprost per day, respectively.” (opens the source at this quote in a new tab)

Retreatment after drug depletion

“We believe the BIM-DRS could be implanted in a standalone procedure, enable retreatment of patients who had received the BIM-IOL System, and offer extended care for pseudophakic patients with OAG or OHT.” (opens the source at this quote in a new tab)

Proposed labeled dosing and retreatment interval

No evidence found.